ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2019
Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay.
Open access · hybridAbstract read
In one paragraph
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 80 citations in OpenAlex.
- Plasma chaperone-mediated autophagy associated protein HSPA8 combined with white matter hyperintensities serves as the predictive marker of early-stage Alzheimer's disease.Frontiers in aging neuroscience · 2026Article
- Systemic proteomic and organ aging signatures associated with plasma Aβ oligomerization in a Korean cohort: a cross-sectional study.Frontiers in aging neuroscience · 2026Article
- Plasma proteomic Alzheimer's risk score: Biological age clock and pseudotime trajectory.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Mendelian Randomization Reveals Unidirectional Links Between Amyloid-β and Tau in Alzheimer's Disease.Dementia and neurocognitive disorders · 2025Article
- Current Methods in Clinical Alzheimer's Disease Research and Diagnosis.Molecular diagnosis & therapy · 2025Review
- Article
- Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration.Nature aging · 2025Article
- Unleashing the Power of Multiomics: Unraveling the Molecular Landscape of Peripheral Neuropathy.Annals of clinical and translational neurology · 2025Review
- APOE genotype and brain amyloid are associated with changes in the plasma proteome in elderly subjects without dementia.Annals of clinical and translational neurology · 2025Article
- Identifying proteomic prognostic markers for Alzheimer's disease with survival machine learning: The Framingham Heart Study.The journal of prevention of Alzheimer's disease · 2025Article
- Approaches and Challenges in Characterizing the Molecular Content of Extracellular Vesicles for Biomarker Discovery.Biomolecules · 2024Review
- Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Identifying Proteomic Prognostic Markers for Alzheimer's Disease with Survival Machine Learning: the Framingham Heart Study.medRxiv : the preprint server for health sciences · 2024Article
- Blood-Based Proteomics for Adult-Onset Focal Dystonias.Annals of neurology · 2024Article
- Using blood transcriptome analysis for Alzheimer's disease diagnosis and patient stratification.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning.Alzheimer's research & therapy · 2023Article
- Ultrasensitive Protein Detection Technologies for Extracellular Vesicle Measurements.Molecular & cellular proteomics : MCP · 2023Article
- Are EPB41 and alpha-synuclein diagnostic biomarkers of sport-related concussion? Findings from the NCAA and Department of Defense CARE Consortium.Journal of sport and health science · 2023Article
- Proteome Network Analysis Identifies Potential Biomarkers for Brain Aging.Journal of Alzheimer's disease : JAD · 2023Article
- Identification of a possible proteomic biomarker in Parkinson's disease: discovery and replication in blood, brain and cerebrospinal fluid.Brain communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
53 authors at 20 institutions in 14 countries.
Liu ShiDepartment of Psychiatry, University of Oxford, Oxford, UK. Electronic address: liu.shi@psych.ox.ac.uk.
Sarah WestwoodDepartment of Psychiatry, University of Oxford, Oxford, UK.
Alison L BairdDepartment of Psychiatry, University of Oxford, Oxford, UK.
Laura WinchesterDepartment of Psychiatry, University of Oxford, Oxford, UK.
Valerija DobricicLübeck Interdisciplinary Platform for Genome Analytics, Institutes of Neurogenetics and Cardiogenetics, University of Lübeck, Lübeck, Germany.
Fabian KilpertLübeck Interdisciplinary Platform for Genome Analytics, Institutes of Neurogenetics and Cardiogenetics, University of Lübeck, Lübeck, Germany.
Shengjun HongLübeck Interdisciplinary Platform for Genome Analytics, Institutes of Neurogenetics and Cardiogenetics, University of Lübeck, Lübeck, Germany.
Andre FrankeInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Abdul HyeMaurice Wohl Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK.
Nicholas J AshtonMaurice Wohl Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK; Department of Psychiatry and Neurochemistry, University of Gothenburg, Mölndal, Sweden; Wallenberg Centre for Molecular & Translational Medicine, University of Gothenburg, Gothenburg, Sweden; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.
Angharad R MorganDementia Research Institute Cardiff, Cardiff University, Cardiff, UK.
Isabelle BosDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands.
Stephanie J B VosAlzheimer Center, VU University Medical Center, Amsterdam, the Netherlands.
Noel J BuckleyDepartment of Psychiatry, University of Oxford, Oxford, UK.
Mara Ten KateAlzheimer Center, VU University Medical Center, Amsterdam, the Netherlands.
Philip ScheltensAlzheimer Center, VU University Medical Center, Amsterdam, the Netherlands.
Rik VandenbergheUniversity Hospital Leuven, Leuven, Belgium.
Silvy GabelUniversity Hospital Leuven, Leuven, Belgium; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Belgium.
Karen MeersmansUniversity Hospital Leuven, Leuven, Belgium; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Belgium.
Sebastiaan EngelborghsCenter for Neurosciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium; Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium; Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; Department of Neurology, VUB University Hospital Brussels (UZ Brussel), Brussels, Belgium.
Ellen E De RoeckCenter for Neurosciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium; Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium; Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
Kristel SleegersInstitute Born-Bunge, University of Antwerp, Antwerp, Belgium; Neurodegenerative Brain Diseases Group, Center for Molecular Neurology, VIB, Edegem, Belgium.
Giovanni B FrisoniUniversity of Geneva, Geneva, Switzerland; IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Olivier BlinAIX Marseille University, INS, Ap-hm, Marseille, France.
Jill C RichardsonNeurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, UK.
Régis BordetUniversity of Lille, Inserm, CHU Lille, Lille, France.
José L MolinuevoAlzheimer's disease & other cognitive disorders unit, Hopsital Clínic-IDIBAPS, Barcelona, Spain; Barcelona Beta Brain Research Center, Universitat Pompeu Fabra, Barcelona, Spain.
Lorena RamiBarcelona Beta Brain Research Center, Universitat Pompeu Fabra, Barcelona, Spain.
Anders WallinInstitute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Petronella KettunenInstitute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Magda Tsolaki1st Department of Neurology, AHEPA University Hospital, Makedonia, Thessaloniki, Greece.
Frans VerheyDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands.
Alberto LleóHospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Daniel AlcoleaDepartment of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Julius PoppUniversity Hospital of Lausanne, Lausanne, Switzerland; Geriatric Psychiatry, Department of Mental Health and Psychiatry, Geneva University Hospitals, Geneva, Switzerland.
Gwendoline PeyratoutUniversity Hospital of Lausanne, Lausanne, Switzerland.
Pablo Martinez-LageCITA-Alzheimer Foundation, San Sebastian, Spain.
Mikel TaintaCITA-Alzheimer Foundation, San Sebastian, Spain.
Peter JohannsenDanish Dementia Research Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Charlotte E TeunissenNeurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.
Yvonne Freund-LeviDepartment of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, and Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Psychiatry in Region Örebro County and School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Department of Old Age Psychiatry, Psychology and Neuroscience, Kings College London, London, UK.
Lutz FrölichDepartment of Geriatric Psychiatry, Zentralinstitut für Seelische Gesundheit, University of Heidelberg, Mannheim, Germany.
Cristina Legido-QuigleyKings College London, London, UK; The Systems Medicine Group, Steno Diabetes Center, Gentofte, Denmark.
Frederik BarkhofDepartment of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherland; UCL Institutes of Neurology and Healthcare Engineering, London, UK.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL, London, UK; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
Susan BakerJanssen R&D, Titusville, NJ, USA.
B Paul MorganDementia Research Institute Cardiff, Cardiff University, Cardiff, UK.
Johannes StrefferReference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium; Janssen R&D, LLC, Beerse, Belgium.
Pieter Jelle VisserDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands; Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden.
Lars BertramLübeck Interdisciplinary Platform for Genome Analytics, Institutes of Neurogenetics and Cardiogenetics, University of Lübeck, Lübeck, Germany; Department of Psychology, University of Oslo, Oslo, Norway.
Simon LovestoneDepartment of Psychiatry, University of Oxford, Oxford, UK; Janssen-Cilag UK, formerly Department of Psychiatry, University of Oxford, Oxford, UK.
Alejo J Nevado-HolgadoDepartment of Psychiatry, University of Oxford, Oxford, UK.
University of Oxford · GBAmsterdam UMC Location VUmc · NLUniversity of Antwerp · BEUniversity of Gothenburg · SEUniversity of Lübeck · DEFundacion CITA Alzheimer · ESHospital de Sant Pau · ESKing's College London · GBKU Leuven · BEMaastricht University · NLPompeu Fabra University · ESUniversity Hospital of Lausanne · CHAHEPA University Hospital · GRAix-Marseille Université · FRAmsterdam Neuroscience · NLCopenhagen University Hospital · DKGlaxoSmithKline (United Kingdom) · GBHeidelberg University · DEJanssen (United Kingdom) · GBJanssen (United States) · US
Funding
Medical Research Council MC_PC_17215Medical Research Council MR/L023784/2
Abstract
introductionPlasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins.
methods4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid.
resultsA panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. DISCUSSION: The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition.
Indexed as
Alzheimer DiseaseProteomicsAgedAge FactorsAmyloidApolipoprotein E4BiomarkersBrainEuropeFemaleHumansMaleMiddle AgedAmyloidApolipoprotein E4BiomarkersAmyloid βCausal relationshipPlasma proteomicsReplicationSOMAscan assayTau
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.